Aileron Therapeutics Inc expected to post a loss of 8  cents a share - Earnings Preview

Rein Therapeutics

06/05/2022 13:33

* Aileron Therapeutics Inc  ALRN.OQ   ALRN.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * ​Refinitiv's mean analyst estimate for Aileron
Therapeutics Inc
is for a loss of 8 cents per share. For the same quarter last
year, the company reported a loss of 6 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 27.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Aileron
Therapeutics Inc is $3.5​, above​ its last closing price
of $0.43. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.08       -0.08      -0.09     Missed  -17.4
 Dec. 31 2022              -0.08      -0.08     Met     0
 Sep. 30 2021  -0.07       -0.07      -0.07     Met     0​
 Jun. 30 2021  -0.07       -0.07      -0.06     Beat    18.2
 ​​Mar.        -0.05       -0.05      -0.08     Missed  -50
 31 2021                                                
 Dec. 31 2020  -0.12       -0.13      -0.12     Beat    5.9​
 Sep. 30 2020  -0.13       -0.15      -0.13     Beat    12.2
 Jun. 30 2020  -0.16       -0.19      -0.14     Beat    25.3
 This summary was machine generated May 6 at 12:33 GMT.  All
figures in US dollars  unless otherwise stated